

# NANOBIOTIX

## EXPANDING LIFE

### Nanobiotix: Voting Rights and Shares Capital of the Company

July 8, 2022

*In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)*

PARIS--(BUSINESS WIRE)--Jul. 8, 2022-- Regulatory News:

Nanobiotix (Paris:NANO)(NASDAQ:NBTX)

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website: [www.nanobiotix.com](http://www.nanobiotix.com)

Date	Number of Shares Outstanding	Total number of voting rights	
		Total voting rights, theoretical <sup>(1)</sup>	Total voting rights, exercisable <sup>(2)</sup>
June 30, 2022	34,875,872	36,329,077	36,303,371

<sup>(1)</sup> The total number of theoretical (or "gross") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

<sup>(2)</sup> The total number of exercisable at a Shareholders' Meeting (or "net") voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

#### About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220708005299/en/): <https://www.businesswire.com/news/home/20220708005299/en/>

Nanobiotix

#### Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

#### Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

Media Relations

France – **Ulysse Communication**

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

Source: Nanobiotix